Patheon IncTSX: PTI

Patheon Receives Reply to FDA Response Letter

· Issued by Patheon Inc via CNW
TORONTO, Oct. 18 /CNW/ - Patheon Inc. (TSX: PTI) announced today that its
subsidiary, CEPH International Corporation, received a reply from the U.S.
Food and Drug Administration (FDA) to its response letter filed on October 6,
2005 in response to the FDA Warning Letter dated September 13, 2005.
In its reply, the FDA stated it had found that the commitments to the
corrective actions outlined in CEPH's response letter will address the FDA's
concerns raised in the Warning Letter.
CEPH is currently implementing the corrective action program. During the
next few days, CEPH will commence manufacturing qualification and validation
batches of the Omnicef oral powder for suspension product in accordance with
the corrective action program. CEPH anticipates that by early November it will
complete qualification and validation testing of these batches of product and,
subject to satisfactory test results, will release these batches of product to
the client.
The FDA has indicated that it wants to be notified when production of the
product has been re-initiated. CEPH currently expects that during the month of
November it will be in a position to notify the FDA that production has been
re-initiated and that it will be prepared for an FDA re-inspection to verify
the implementation of the corrective actions.

Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug
development and manufacturing services to the international pharmaceutical
industry. With the addition of its wholly owned subsidiary MOVA Pharmaceutical
Corporation, acquired in December 2004, Patheon operates a network of
14 facilities in the United States, Canada and Europe, employing more than
5,900 people and serving a client base of 180 pharmaceutical and biotechnology
companies.

This news release contains forward-looking statements with respect to
Patheon, including its business operations and strategy and financial
performance and condition. Although management believes that the expectations
reflected in such forward-looking statements are reasonable, such statements
involve risks and uncertainties. Actual results may differ materially from
those expressed or implied by such forward-looking statements. Factors that
could cause actual results to differ materially from expectations include, but
are not limited to, currency fluctuations, the level of outsourcing services
required by the pharmaceutical companies (and in particular our clients), the
impact of changes in pharmaceutical development and manufacturing regulations
and general economic and market factors (including inflation and changes in
laws) and other factors discussed in materials filed with applicable
securities regulatory authorities from time to time.
%SEDAR: 00001700E

Patheon Inc on 6ix

Earlier from Patheon

Later from Patheon

All Patheon news releases